REGENXBIO's Duchenne Gene Therapy Targets 2027 Global Launch, Challenging Sarepta's Market Lead
US biotech REGENXBIO is on course to commercialise RGX-202, its gene therapy for Duchenne Muscular Dystrophy, by 2027 after completing enrolment in its pivotal trial ahead of schedule. With top-line data expected in early Q2 2026 and a US regulatory filing planned for mid-year, the therapy's cleaner safety profile positions it as a serious rival to the only currently approved DMD gene therapy. The programme also has implications for the estimated 300,000 DMD patients worldwide who have historica
ViaNews Editorial Team•